ABVS结合BI-RADS对乳腺癌新辅助化疗的评估价值

Assessment Value of Automatic Breast Volume Scanning Combined with Bread Imaging Reporting and Data System for Neoadjuvant Chemotherapy in Breast Cancer

目的探讨乳腺自动全容积扫查系统(Automatic Breast Volume Scanning,ABVS)结合乳腺图像报告和数据系统(Bread Imaging Reporting And Data System,BI-RADS)对乳腺癌新辅助化疗患者的评估价值。方法选取2014年1月~2016年1月期间我院乳腺外科乳腺癌新辅助化疗患者98例,根据新辅助化疗疗效将患者分为治疗有效组(n=65)与治疗无效组(n=33),分析两组ABVS、BIRADS对乳腺癌新辅助化疗患者疗效的评估作用。结果 ABVS显示:治疗前两组肿瘤面积与肿瘤体积比较差异无统计学意义(P>0.05);治疗后治疗有效组患者上述指标均明显低于同组治疗前与治疗无效组,比较差异具有统计学意义(P<0.05)。治疗前两组边缘清晰、弹性评分低与后方回声增强所占比例比较差异无统计学意义(P>0.05);治疗后治疗有效组上述比例均明显高于治疗前与治疗无效组(P<0.05)。BI-RADS结果显示:治疗前两组患者阳性病变率比较差异无统计学意义(P>0.05);治疗后全部患者阳性病变率均明显降低,比较差异具有统计学意义(P<0.05),其中治疗有效组患者阳性病变率均明显低于治疗无效组,比较差异具有统计学意义(P<0.05)。结论ABVS结合BI-RADS对乳腺癌新辅助化疗疗效提供更为全面与规范化的评估价值。

Objective To explore assessment value of Automatic Breast Volume Scanning（ABVS）combined with Bread Imaging Reporting and Data System（BI-RADS）for neoadjuvant chemotherapy in breast cancer. Methods 98 cases of breast cancer neoadjuvant chemotherapy patients were selected from January 2014 to January 2016 from Breast surgery Department of our hospital. According to curative effect of neoadjuvant chemotherapy, they were divided into effectivity group（n=65）and invalidity group（n=33）, assessment value of ABVS and BI-RADS for neoadjuvant chemotherapy efficacy of the two groups were analyzed. Results ABVS showed that before treatment, comparative difference of tumor area and tumor volume between the two groups had no statistical significance（P〉0.05）; after treatment, the above indicators of effectivity group were significantly lower than those of pretherapy of the same group and those of invalidity group, and had statistically significant difference（P〈0.05）. Before treatment, the proportion of clear border, low elasticity score and rear echogenicity between the two groups had no statistically significant difference（P〉0.05）; after treatment, these proportion of effectivity group were significantly higher than those of pre-therapy and invalidity group（P〈0.05）. According to BI-RADS, before treatment, positive lesions rates between the two groups had no statistically significant difference（P〉0.05）; after treatment, positive lesions rates of all patients was significantly lower than that of pre-therapy, comparative difference was statistically significant（P〈0.05）, positive lesions rates of effectivity group was significantly lower than that of invalidity group, comparative difference was statistically significant（P〈0.05）. Conclusion ABVS combined with BI-RADS provides more comprehensive and standardized assessment value in the curative effect of breast cancer neoadjuvant chemotherapy.